ArticleAnnals of internal medicine2026
Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness : A Cohort Study in Two U.S. Cities.
Article in Annals of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLittle was known about persistent sequelae of mpox before the 2022 multinational clade II mpox virus outbreak.
objectiveTo characterize post-mpox sequelae 11 to 18 months after acute mpox diagnosis and compare outbreak-associated psychosocial and behavioral impact between at-risk persons who had or did not have mpox.
designCohort study.
settingNew York City, New York, and Houston, Texas.
participantsAdults attending HIV, pre-exposure prophylaxis, or sexually transmitted infection clinics diagnosed with mpox during May 2022 to January 2023 (post-mpox) or at risk for but never diagnosed with mpox (no-mpox). MEASUREMENTS: All participants completed psychosocial and behavioral self-assessments. A clinician also assessed post-mpox participants by clinical history and physical examination; persisting mpox physical sequelae were classified by tissue affected and effect on appearance or function. Associations between post-mpox physical sequelae and medical history, acute mpox severity, and sociodemographic characteristics were assessed using marginally adjusted probabilities (presented as risk ratios with 95% CIs).
resultsA total of 154 post-mpox and 201 no-mpox participants were enrolled. The proportion of participants reporting increased psychobehavioral symptoms was generally similar between groups. Fifty-eight percent (89 of 154) of post-mpox participants had at least 1 persistent sequela; 56% (86 of 154) were appearance related, of which 51% (44 of 86) occurred at 2 or fewer sites. Thirteen percent (20 of 154) of post-mpox participants had functional sequelae, of whom 50% (10 of 20) and 35% (7 of 20) had ongoing anorectal and urinary dysfunction, respectively. LIMITATIONS: Participants may not be representative of mpox-affected and susceptible populations. Findings may over- or underestimate frequency or severity of severe mpox sequelae.
conclusionPost-mpox sequelae frequently persisted 11 to 18 months after acute mpox, with limited body distribution or physical morbidity but with continued social and sexual effects. PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.